Chronic disease and its therapeutic drugs may effect on the postoperative 5-year survival rate of lung cancer patients

doi:10.5246/jcps.2017.02.014

Journal of Chinese Pharmaceutical Sciences ›› 2017, Vol. 26 ›› Issue (2): 147-155.DOI: 10.5246/jcps.2017.02.014

• Original articles • Previous Articles Next Articles

Chronic disease and its therapeutic drugs may effect on the postoperative 5-year survival rate of lung cancer patients

Liang Shi¹, Zeng Wang¹, Tingting Yu^2*, Liang Xia¹

1. Zhejiang Cancer Hospital, Hangzhou 310022, China
2. Xihu District Hangzhou SanDu Town Community Health Service Center, Hangzhou 310030, China

Received:2016-11-15 Revised:2016-11-28 Online:2017-02-28 Published:2016-12-18
Contact: +86-15068193184, E-mail: 435517746@qq.com
Supported by:
General Research Program of Medical Health in Zhejiang Province (Grant No. 2014KYB039), Zhejiang Provincial Program for the Zhejiang Medical and Health Science and Technology Program (Grant No. 2015KYB071), Scientific Research Fund Project of Integrated Chinese and Western Medicine Institute in Zhejiang Province (Grant No. 2014LYK021), Science and Technology in Zhejiang Province Chinese Medicine Program (Grant No. 2016ZA038), and 1022 Talent Training Program of Zhejiang Cancer Hospital.

Abstract

Abstract:

In this study, we aimed to investigate the influencing factors of postoperative 5-year survival rate in non small-cell lung cancer (NSCLC) patients with stage I-III. We enrolled 220 patients who underwentsurgical operation and survived longer than 3 months, with histologically confirmed adenocarcinoma or squamous cell carcinoma from Jan. 2009 to Dec. 2009. Multiple variables, like age, gender, smoking, alcohol, obesity, family history of cancer, diabetes, hypertension, antidiabetic drugs, tumor staging, pathology, treatments, surgical side as well as lipid levels, were selected. We found that tumor staging was associated with 5-year survival rate of stage I-III NSCLC patients by univariate analysis. Furthermore, diabetes mellitus, hypertension andsurgical side were associated with the overall survival of NSCLC patients with stage I, stageⅡand stageIII, respectively. In conclusion, the status of chronic disease had potential effect on the postoperative 5-year survival rate of lung cancer patients.

Key words: Non small-cell, Lung cancer, 5-Year survival rate, Influencing factors

CLC Number:

R969

Supporting:

Liang Shi, Zeng Wang, Tingting Yu, Liang Xia. Chronic disease and its therapeutic drugs may effect on the postoperative 5-year survival rate of lung cancer patients[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(2): 147-155.

References

[1] Siegel, R.; Naishadham, D.; Jemal, A. Cancer J. Clin. 2013, 63, 11-30.
[2] Owonikoko, T.K.; Ragin, C.C.; Belani, C.P. J. Clin. Oncol. 2007, 25, 5570-5577.
[3] Zimmermann, F.B.; Molls, M.; Jeremic, B. Semin. Surg. Oncol. 2003, 21, 122-127.
[4] Awabata, N.; Miyaoka, E.; Asamura, H. J. Thorac. Oncol. 2011, 6, 1229-1235.
[5] Asamura, H.; Goya,T.; Koshiishi,Y. J. Thorac. Oncol. 2008, 3, 46–52
[6] Brundage, M.D.; Davies, D.; Mackillop, W. J. Chest. 2002, 122, 1037-1057.
[7] Birim, O.; Zuydendorp, H.M.; Maat, A.P. Ann Thorac. Surg. 2003, 76, 1796-1801.
[8] Park, C.; Lee, I.J.; Jang, S.H. J. Thorac. Dis. 2014, 6, 1420-1428.
[9] Myrdal, G.; Gustafsson, G.; Lambe, M. Eur. J. Cardiothorac. Surg. 2001, 20, 694-699.
[10] Uehara, H.; Nakao, M.; Mun, M. Ann Thorac. Cardiovasc. Surg. 2015, 21, 345-353.
[11] Zimmermann, F.B.; Molls, M.; Jeremic, B. Semin. Surg. Oncol. 2003, 21, 122-124.
[12] Uramoto, H.; Tanaka, F. Transl. Lung. Cancer Res. 2014, 3, 242-249.
[13] Hotta, K.; Fujiwara, Y.; Kiura, K.J. Thoracic. Oncol. 2007, 5, 402-407.
[14] Jeremic, B.; Milicic, B.; Dagovic, A.J. Cancer. Res. Clin. Oncol. 2003, 129, 114-122.
[15] Falcone, A.J. Cancer Res. Clin. Oncol. 2008, 134, 1143-1149.
[16] Hashizume, S.; Nagayasu, T.; Hayashi, T. Lung Cancer. 2009, 65, 363-370.
[17] Sawada, S.; Yamashita, N.; Suehisa, H. Chest. 2013, 144, 1238-1244.
[18] Brundage, M.D.; Davies, D.; Mackillop. W. J. Chest. 2002, 122, 1037-1057.
[19] Goldstraw, P.; Crowley, J.; Chansky, K. J. Thorac. Oncol. 2007, 2, 706-714.
[20] Huang, Y.C.; Lin, J.K.; Chen, W.S. J. Cancer. Res. Clin. Oncol. 2011, 137, 211-220.
[21] Sperti, C.; Pasquali, C.; Piccoli, A. Br. J. Surg. 1996, 83, 625-631.
[22] Toyoda, H.; Kumada, T.; Nakano, S. Cancer. 2001, 91, 957-963.
[23] Dawson, S.I. Cancer. 2004, 100, 149-155.
[24] Spranger, J.; Kroke, A.; Mohlig, M. Diabetes. 2003, 52, 812-817.
[25] Wang, Y.; James, M.; Wen, W. Mol. Cancer Ther. 2010, 9, 3074-3082.
[26] Zhou, R.; Myers, Y. J. Clin. Invest. 2001, 108, 1167-1174.
[27] Dowling, M.; Zakikhani, I.G.; Fantus, G. Cancer Res. 2007, 67, 10804-10812.
[28] Lin, C.C.; Yeh, H.; Huang, L. Am. J. Respiratory Cell Molecul. 2013, 49, 241-250.
[29] Teixeira, S.F.; Guimar es, I.S.; Madeira, K.P. Jornal Brasileiro De Pneumologia Publicacao Oficial Da Sociedade Brasileira De Pneumologia E Tisilogia. 2013, 39, 644-649.
[30] Mishra, P.K.; Pandey, R.; Shackcloth, M.J. Eur. J. Cardiothorac. Surg. 2009, 35, 439-443.
[31] Moro-Sibilot, D.; Aubert, A.; Diab, S. Eur. Respir. J. 2005, 26, 480-486.
[32] Alex, B. J. Hypertension. 2005, 23, 1473-1475
[33] Schuller, H.M. Oncotarget. 2010, 1, 466-469
[34] Marrer, é.; Wagner, A.; Montaye, M. Eur. J. Cancer Prev. 2013, 22 , 286-293.
[35] Motoji, S.; Noriko, T.; Makiko, N.M. PLoS One. 2012, 7, e31954.
[36] Motta, M.; Giugno, I.; Ruello, P. Minerva Med. 2001, 92, 301-305.
[37] Stojiljkovic, D.; Santrac, N.; Goran, M. J. Buon. 2016, 21, 221-226.
[38] Yano, M.; Yoshida, J.; Koike, T. World J. Surg. 2016, 1-10.
[39] Zhang, T.; Jiang, Y.; Qu, X. PLoS One. 2014, 9, e111494.

Chronic disease and its therapeutic drugs may effect on the postoperative 5-year survival rate of lung cancer patients

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 10

Recommended Articles

Metrics

Comments

[1]	Kexin Wang, Shengnan Tian, Jia Wang, Jin Jin, Tingting Wang, Licang Zhang, Huanlong Liu. Investigation and research on medication risk of Shijiazhuang urban residents based on KAP Theory [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(9): 755-763.
[2]	Wenxia Liu, Jun Ma, Zhao Yang, Bin Jiang. Influencing factors of generic drug substitution in China—from the perspective of psychiatric patients in "4 + 7" pilot cities [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(4): 317-321.
[3]	Ciyan Peng, Jing Chen, Sini Li, Jianhe Li, Liubao Peng. Study of the economic burden and influencing factors on stroke patients in Central China in the post-epidemic era [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(7): 545-555.
[4]	Shaohong Luo, Liangliang Dong, Yiyuan Li, Dan Xu, Min Chen. Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(3): 253-263.
[5]	Jiale Li, Yan Yang, Zhaoqi Huang, Xiaolan Mo. Efficacy evaluation and influencing factors analysis of combined estrogen in the treatment of labial adhesion in children [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(12): 976-985.
[6]	Shen Lin, Xin Rao, Yiyuan Li, Xiuhua Weng, Changlian Wang. Cost-effectiveness analysis of second-line chemotherapy strategies for patients with advanced non-squamous non-small cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(8): 542-553.
[7]	Eric Wei Chiang Chan, Chen Wai Wong, Siu Kuin Wong, Yew Woh Hui, Joash Ban Lee T. Emodin and shikonin (quinones): an overview of their chemistry, plant sources, pharmacology and cytotoxic activities against lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(1): 1-12.
[8]	Dehua Zhao, Mingming Chu, Jing Chen, Jisheng Wang. Meta-analysis of gemcitabine at 30 min standard-dose infusion versus prolonged low-dose infusion for advanced non-small cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(10): 763-770.
[9]	Ming Hua, Xiwei Ji, Runtao Li, Shuangmin Ji, Jian Li, Qingyu Yao, Lijie Wang, Fangran Hao, Wei Lu, Tianyan Zhou. Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of TM208 on non-small cell lung cancer xenograft [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(7): 502-511.
[10]	Zhenzhen Mou, Siyuan Wang, Qinghong Su, Yin Yuan, Jingyun Li, Lijie Wang, Qingyu Yao, Shuangmin Ji, Wei Lu, Tianyan Zhou. Cabozantinib enhances the response of NSCLC cells with wild-type EGFR to erlotinib and pharmacodynamic modeling of their sequential combinations [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(11): 799-813.